NDA 021163 · Sandoz Canada INC
Infuvite Adult
Alpha-Tocopherol Acetate, Ascorbic Acid, Biotin, Cholecalciferol, Cyanocobalamin, Dexpanthenol, Folic Acid, Niacinamide, Pyridoxine Hydrochloride, Riboflavin 5'-Phosphate Sodium, Thiamine Hydrochloride, Vitamin A Palmitate, Vitamin K · Intravenous
Last checked: Nov 20, 2026Latest source record: Nov 6, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
May 18, 2000
Approved uses
1
Original approval plus efficacy supplements
Registered trials
143
39 Phase 3, 8 recruiting
FAERS reports
141
51 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 6, 2024.
INFUVITE ADULT is a combination of vitamins indicated for the prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition. The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. INFUVITE ADULT is a combination of vitamins indicated for prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition ( 1 )
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- INFUVITE ADULT · ALPHA-TOCOPHEROL ACETATE 2 IU/ML; ASCORBIC ACID 40MG/ML; BIOTIN 12MCG/ML; CHOLECALCIFEROL 40 IU/ML; CYANOCOBALAMIN 1MCG/ML; DEXPANTHENOL 3MG/ML; FOLIC ACID 120MCG/ML; NIACINAMIDE 8MG/ML; PYRIDOXINE HYDROCHLORIDE 1.2MG/ML; RIBOFLAVIN 5'-PHOSPHATE SODIUM 0.72MG/ML; THIAMINE HYDROCHLORIDE 1.2MG/ML; VITAMIN A PALMITATE 660 IU/ML; VITAMIN K 30MCG/ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
- INFUVITE ADULT · ALPHA-TOCOPHEROL ACETATE 2 IU/ML; ASCORBIC ACID 40MG/ML; BIOTIN 12MCG/ML; CHOLECALCIFEROL 40 IU/ML; CYANOCOBALAMIN 1MCG/ML; DEXPANTHENOL 3MG/ML; FOLIC ACID 120MCG/ML; NIACINAMIDE 8MG/ML; PYRIDOXINE HYDROCHLORIDE 1.2MG/ML; RIBOFLAVIN 5'-PHOSPHATE SODIUM 0.72MG/ML; THIAMINE HYDROCHLORIDE 1.2MG/ML; VITAMIN A PALMITATE 660 IU/ML; VITAMIN K 0.03MG/ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Alpha-Tocopherol" as an intervention, any sponsor and status, largest first.
- S0000 Selenium and Vitamin E in Preventing Prostate CancerPivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00006392 · 35,533 participants · Start Jul 2001 · Primary completion May 2011
Drug: Vitamin E; Selenium · For: Prostate Cancer
Sites: Chicago, Illinois; Joliet, Illinois; Maywood, Illinois · 13 sites in all
- S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000Pivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00784225 · 13,475 participants · Start Jul 2004 · Primary completion Nov 2017
Drug: selenium; vitamin E and 2 more · For: Cataract; Macular Degeneration
Sites: Boston, Massachusetts
- Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)Pivotal-lookingCompleted
The George Washington University Biostatistics CenterAcademic, hospital or other
NCT00135707 · 10,154 participants · Start Jun 2003 · Primary completion Oct 2008
Drug: Dietary Supplement/Vitamins; Placebo for Vitamin C and Vitamin E · For: Preeclampsia
Sites: Birmingham, Alabama; Chicago, Illinois; Detroit, Michigan · 16 sites in all
- S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000Pivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00706121 · 8,094 participants · Start Jun 2008 · Primary completion Oct 2015
Drug: Vitamin E; Selenium and 2 more · For: Colorectal Cancer; Precancerous Condition
Sites: Tucson, Arizona
- Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)Pivotal-lookingCompleted
Jiangsu Rec-Biotechnology Co., Ltd.Industry
NCT05084989 · 948 participants · Start Jan 31, 2022 · Primary completion Aug 18, 2022
Drug: Part1:Recombinant two-component COVID-19 vaccine (CHO cell); Part1: Placebo and 2 more · For: COVID-19
Sites: Roxas City, Philippines
- A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's DiseasePivotal-lookingCompleted
US Department of Veterans AffairsFederal agency
NCT00235716 · 613 participants · Start Aug 2007 · Primary completion Sep 2012
Drug: dl-alpha-tocopherol; Memantine and 3 more · For: Alzheimer's Disease
Sites: Bay Pines, Florida; Miami, Florida; Iowa City, Iowa · 14 sites in all
- Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy LossPivotal-lookingCompleted
University of JenaAcademic, hospital or other
NCT00400387 · 449 participants · Start Nov 2006 · Primary completion Dec 2012
Drug: Fragmin P Forte (dalteparin sodium) · For: Abortion, Habitual
Sites: Dobl, Austria; Halle, Germany; Dresden, Germany · 12 sites in all
D. Walter WrayAcademic, hospital or other
NCT02966665 · 420 participants (planned) · Start Sep 2008 · Primary completion Aug 2030
Drug: BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate; BQ-123 and 3 more · For: Chronic Obstructive Pulmonary Disease; Pulmonary Artery Hypertension; Heart Failure and 1 more
Sites: Salt Lake City, Utah
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- flushing32
- dyspnoea31
- chest discomfort25
- infusion related reaction18
- nausea15
- vomiting14
- dizziness13
- maternal exposure during pregnancy12
- hypersensitivity10
- anaphylactic reaction9
- chest pain8
- feeling abnormal8
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 7 |
| 2019 | 13 |
| 2020 | 10 |
| 2021 | 14 |
| 2022 | 20 |
| 2023 | 18 |
| 2024 | 12 |
| 2025 | 10 |
| 2026 | 14 |
Recalls
1 FDA enforcement reports for this application.
Apr 25, 2025 · Class II · Ongoing
Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected...
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Associations of Dietary Cholesterol, Serum Cholesterol, and Egg Consumption With Overall and Cause-Specific Mortality: Systematic Review and Updated Meta-Analysis.
Zhao B, Gan L, Graubard BI, et al. · Circulation 2022 · Meta-Analysis, Systematic Review
- Fiber and whole grain intakes in relation to liver cancer risk: An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies.
Watling CZ, Wojt A, Florio AA, et al. · Hepatology 2024 · Systematic Review, Meta-Analysis
- Metabolomics changes after rTMS intervention reveal potential peripheral biomarkers in methamphetamine dependence.
Su H, Yang P, Chen T, et al. · Eur Neuropsychopharmacol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Vitamin E, Alpha-Tocopherol, and Its Effects on Depression and Anxiety: A Systematic Review and Meta-Analysis.
Lee ARYB, Tariq A, Lau G, et al. · Nutrients 2022 · Meta-Analysis, Systematic Review
- Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.
Evans JR, Lawrenson JG · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.
Evans JR, Henshaw K · Cochrane Database Syst Rev 2008 · Meta-Analysis, Systematic Review
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.